Article 31 governs clinical trials on incapacitated subjects: trial must be essential with respect to the incapacitated population, expected benefits to the population must outweigh the risks, and consent is given by the legally designated representative with the subject's assent where possible. Article 32 governs clinical trials on minors: similar safeguards with assent of the minor where age-appropriate, and the protocol must contain specific provisions for the minor's age and maturity.
This control maps to 1 controls across 1 other frameworks. If you already hold one of them, the evidence you collected for it is the starting point here rather than new work.
Every mapping shown was judged rather than inferred from wording similarity, and the ones that failed review are published too. See the coverage reports and what was rejected.
The graph holds this control, the 1 it maps to, and the evidence behind each claim, over MCP and REST.